Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Assets: 2009-2025

Historic Other Non-Current Assets for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to $358,000.

  • Northwest Biotherapeutics' Other Non-Current Assets fell 4.28% to $358,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $358,000, marking a year-over-year decrease of 4.28%. This contributed to the annual value of $365,000 for FY2024, which is 1.11% up from last year.
  • Northwest Biotherapeutics' Other Non-Current Assets amounted to $358,000 in Q3 2025, which was down 3.24% from $370,000 recorded in Q2 2025.
  • Northwest Biotherapeutics' Other Non-Current Assets' 5-year high stood at $1.1 million during Q2 2021, with a 5-year trough of $339,000 in Q3 2022.
  • Its 3-year average for Other Non-Current Assets is $364,545, with a median of $363,000 in 2024.
  • Per our database at Business Quant, Northwest Biotherapeutics' Other Non-Current Assets surged by 44.77% in 2021 and then tumbled by 68.71% in 2022.
  • Northwest Biotherapeutics' Other Non-Current Assets (Quarterly) stood at $1.0 million in 2021, then tumbled by 66.70% to $345,000 in 2022, then rose by 4.64% to $361,000 in 2023, then climbed by 1.11% to $365,000 in 2024, then fell by 4.28% to $358,000 in 2025.
  • Its Other Non-Current Assets stands at $358,000 for Q3 2025, versus $370,000 for Q2 2025 and $367,000 for Q1 2025.